RNAx Inks Japanese Distribution Deal with Funakoshi

RNAx said this week that it has signed a deal under which its siRNA oligonucleotide and genetic target validation services will be marketed in Japan exclusively by Funakoshi.

“We are happy to be able to collaborate with Funakoshi to enter the very interesting Japanese market,” RNAx CEO Joerg Poetzsch said in a statement. “Experience has shown that local presence of native experts who are familiar with the customs of a given country plays a key role in successfully operating at a foreign market.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.